Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Ray-Coquard

Showing results (271-280 of 509) with videos related to

Pageof 51
Sort By:
Plos One|August 10, 2011
Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testingFrançoise Ducimetière, Antoine Lurkin, Dominique Ranchère-Vince, et al.
European Journal of Cancer (Oxford, England : 1990)|March 4, 2022
Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patientsPierre Heudel, Bertrand Favier, Marie-Laure Solodky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX StudyNicolas Penel, Binh Nguyen Bui, Jacques-Olivier Bay, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 27, 2022
Impact of early palliative care on additional line of chemotherapy in metastatic breast cancer patients: results from the randomized study OSSGisèle Chvetzoff, Carole Bouleuc, Audrey Lardy-Cléaud, et al.
European Journal of Cancer (Oxford, England : 1990)|May 18, 2010
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)Patrick Schöffski, Jean-Yves Blay, Jacques De Greve, et al.
Plos One|February 4, 2017
Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and exhaustive population-based cohort)Olfa Derbel, Pierre Etienne Heudel, Claire Cropet, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 10, 2024
Primary Vulvar and Vaginal Adenocarcinomas of Intestinal Type Are Closer To Colorectal Adenocarcinomas Than To Carcinomas of Müllerian OriginAlexis Trecourt, Isabelle Treilleux, Daniel Pissaloux, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 12, 2023
The KAT6B::KANSL1 Fusion Defines a New Uterine Sarcoma With Hybrid Endometrial Stromal Tumor and Smooth Muscle Tumor FeaturesAlexis Trecourt, Rihab Azmani, Isabelle Hostein, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 3, 2025
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitorsRamez N Eskander, Jung-Yun Lee, Mansoor Raza Mirza, et al.
Bulletin Du Cancer|March 3, 2020
Detailed overview on rare malignant ovarian tumorsStefanie Aust, Lauriane Eberst, Olivier Tredan, et al.
Pageof 51

Showing results (271-280 of 509) with videos related to

Sort By:
Pageof 51
Plos One|August 10, 2011
Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testingFrançoise Ducimetière, Antoine Lurkin, Dominique Ranchère-Vince, et al.
European Journal of Cancer (Oxford, England : 1990)|March 4, 2022
Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patientsPierre Heudel, Bertrand Favier, Marie-Laure Solodky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX StudyNicolas Penel, Binh Nguyen Bui, Jacques-Olivier Bay, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 27, 2022
Impact of early palliative care on additional line of chemotherapy in metastatic breast cancer patients: results from the randomized study OSSGisèle Chvetzoff, Carole Bouleuc, Audrey Lardy-Cléaud, et al.
European Journal of Cancer (Oxford, England : 1990)|May 18, 2010
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)Patrick Schöffski, Jean-Yves Blay, Jacques De Greve, et al.
Plos One|February 4, 2017
Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and exhaustive population-based cohort)Olfa Derbel, Pierre Etienne Heudel, Claire Cropet, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 10, 2024
Primary Vulvar and Vaginal Adenocarcinomas of Intestinal Type Are Closer To Colorectal Adenocarcinomas Than To Carcinomas of Müllerian OriginAlexis Trecourt, Isabelle Treilleux, Daniel Pissaloux, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 12, 2023
The KAT6B::KANSL1 Fusion Defines a New Uterine Sarcoma With Hybrid Endometrial Stromal Tumor and Smooth Muscle Tumor FeaturesAlexis Trecourt, Rihab Azmani, Isabelle Hostein, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 3, 2025
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitorsRamez N Eskander, Jung-Yun Lee, Mansoor Raza Mirza, et al.
Bulletin Du Cancer|March 3, 2020
Detailed overview on rare malignant ovarian tumorsStefanie Aust, Lauriane Eberst, Olivier Tredan, et al.
Pageof 51